Boston Scientific Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BSX research report →
Range $44 – $71
Price Chart
About the company
Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns.
- CEO
- Michael F. Mahoney
- IPO
- 1992
- Employees
- 59,000
- HQ
- Marlborough, MA, US
AI snapshot
Six angles, distilled from the data.
BSX is in a long corrective regime after a major drawdown from its 52-week high of 101.91, but it has held well above the 52-week low of 39.57. The stock is still below its 200-day average, so the setup remains a recovery phase rather than a confirmed long-term uptrend.
Street sentiment stays constructive, with consensus at Buy and an average target of 53.77 versus a 42.99 last close. Recent calls skewed lower on targets and a few downgrades, but the broader rating mix still leans positive with 33 Buys, 10 Holds, and no Sells.
The earnings profile is solid but not flawless: BSX has beaten in 7 of the last 8 quarters, yet the most recent report matched estimates at 0.73 EPS. Next-year EPS estimates point to 3.1307, so shareholders should watch whether growth re-accelerates after the latest flat print.
Insider activity leans supportive, led by meaningful open-market buying from the CEO and other directors. The large purchase cluster outweighs automatic exercise, vesting, and withholding-related transactions, which look like routine compensation flows rather than a change in conviction.
Profitability remains strong, with a 68.0% gross margin, 19.64% operating margin, and 16.62% net margin. Revenue growth is modest at 1.4% year over year, while EPS growth is still negative at -21.5%, so the market is waiting for earnings momentum to catch up with margins.
BSX screens as a premium-quality medtech name with better margin structure than many peers, but the valuation is not cheap at 13.87x earnings. The setup favors a company that can justify that multiple through steadier growth and continued execution in devices.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $60.85B
- P/E
- 18.14
- Fwd P/E
- 13.27
- PEG
- 0.71
- P/S
- 2.96
- P/B
- 2.43
- EV/EBITDA
- 13.60
- Div Yield
- 0.00%
- Gross Margin
- 70.37%
- Op Margin
- 21.05%
- Net Margin
- 16.56%
- ROE
- 13.87%
- ROIC
- 10.46%
Latest fiscal year · YoY change
- Revenue
- $20.07B+19.9%
- Gross Profit
- $13.85B+34.9%
- Op Income
- $3.97B
- Net Income
- $2.89B+55.7%
- EPS
- $1.96+55.6%
- OCF Growth
- +32.0%
- FCF Growth
- +38.3%
- 52W High
- $101.91
- 52W Low
- $39.57
- 50D MA
- $43.86
- 200D MA
- $53.25
- Beta
- 0.58
- RSI (14)
- 42
- Avg Volume
- 19.51M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Boston Scientific’s Q3 was hit by a cyber incident, and management cut 2026 guidance while warning 2027 will likely be a trough before growth reaccelerates in 2028.· October 28, 2026
- Q3 organic revenue rose 1.5% to $5.14 billion, but adjusted EPS was $0.73, both below guidance after a cyber incident hit operations.
- Adjusted gross margin was 68.0%, down 300 basis points year over year; adjusted operating margin was 26.5%, down 150 basis points.
- Management said the cyber incident reduced Q3 sales growth by about 300 basis points and EPS by about $0.07, with another 200 to 300 basis point revenue drag expected in Q4.
- Full-year 2026 organic revenue growth is now expected to be about 3.75% and adjusted EPS $3.16 to $3.18; Q4 organic revenue is guided to decline 3% to 1%.
- The company sees 2027 as a challenging year, especially for WATCHMAN and EP, but still expects meaningful improvement in 2028 and beyond from launches, restructuring, and Penumbra once closed.
Boston Scientific reported Q3 2026 revenue of $5.14 billion, up 1.5% reported and 1.5% organic/operational year over year. Adjusted EPS was $0.73, down 3% year over year and below the prior guide of $0.80 to $0.82. Adjusted gross margin was 68.0%, down 300 basis points, and adjusted operating margin was 26.5%, down 150 basis points. Management estimated the cyber incident reduced Q3 organic revenue growth by about 300 basis points and EPS by about $0.07. For Q4, the company guided to organic revenue down 3% to down 1% and adjusted EPS of $0.77 to $0.79. Full-year 2026 guidance calls for reported revenue growth of about 4.25%, organic/operational growth of about 3.75%, adjusted EPS of $3.16 to $3.18, adjusted operating margin of about 27.6%, and free cash flow of about $3.6 billion.
Mike Mahoney framed 2026 as a transition year after several years of exceptional growth, saying the cyber incident, WATCHMAN market pressure, and EP share loss are creating a trough in the cycle. He emphasized that the company is taking immediate action through restructuring, operating-structure changes, and focused investment in future launches, and he repeatedly pointed to 2028 as the year Boston Scientific expects to reaccelerate. His tone was candid about near-term challenges but confident that the portfolio, pipeline, and new market opportunities will drive stronger growth later in the decade.
John Monson said the cyber incident materially affected the quarter, with roughly 300 basis points of revenue impact in Q3 and an expected 200 to 300 basis point headwind in Q4 as customer stocking normalizes. He cited Q3 adjusted gross margin of 68.0%, adjusted operating margin of 26.5%, cash on hand of $690 million, gross debt leverage of 1.9x, and free cash flow of $867 million in the quarter. For the full year, he guided to adjusted EPS of $3.16 to $3.18, adjusted operating margin of about 27.6%, tax rate of about 12%, and free cash flow of about $3.6 billion, while noting the restructuring program should deliver over $500 million of savings over three years.
Analysts focused on how much of the Q3 and Q4 weakness came from the cyber incident versus underlying demand, and management said Q3 lost about $150 million of top-line revenue and about $0.07 of EPS from cyber-related disruption and costs. Questions also centered on why 2027 is expected to be weak; management said the base business is still healthy, but WATCHMAN and EP are expected to remain under pressure, China pricing remains a headwind, and the company is being conservative until it sees better market dynamics. Other notable questions addressed pipeline timing and Penumbra: management said some delays are due to V&V work, IDE/CMS timing, and slower-than-hoped enrollment, while Penumbra is now expected to close in early 2027 rather than the previously expected timeline.
Management believes the rest of the portfolio, roughly 75% of the business, is still growing consistently and can support a return to stronger growth once the cycle turns. The company pointed to multiple launch catalysts, a restructuring program already in motion, more than $500 million of expected savings over three years, and Penumbra as incremental support for 2028 and beyond.
Near-term results are pressured by the cyber incident, weaker WATCHMAN and EP trends, and tougher pricing in China, with Q4 and 2027 still looking soft. Management also acknowledged pipeline timing slips in several programs and said 2027 revenue and EPS growth will be challenged excluding Penumbra, with gross margin under pressure from mix, pricing, and ongoing investment.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.3%
- Shares Outstanding
- 1.45B
- Float Shares
- 1.44B
of shares held by institutions
1,583 13F filers
Buy/sell ratio 1.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for BSX, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Ro KhannaHouse · CA17 | Buy | Oct 13, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Oct 7, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Sep 11, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Sep 4, 26 | Filing → |
| Kevin HernHouse · OK01 | Sell | Sep 4, 26 | Filing → |
| Kevin HernHouse · OK01 | Sell | Sep 3, 26 | Filing → |
| Kevin HernHouse · OK01 | Sell | Sep 3, 26 | Filing → |
| Kevin HernHouse · OK01 | Sell | Sep 3, 26 | Filing → |
| Kevin HernHouse · OK01 | Sell | Sep 9, 26 | Filing → |
| Kevin HernHouse · OK01 | Sell | Aug 31, 26 | Filing → |
| Kevin HernHouse · OK01 | Sell | Sep 3, 26 | Filing → |
| Kevin HernHouse · OK01 | Sell | Sep 3, 26 | Filing → |
| Kevin HernHouse · OK01 | Sell | Sep 3, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Aug 18, 26 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 139.69M | ▲ 1.44M |
| Blackrock, Inc. | 125.56M | ▼ 4.12M |
| Vanguard Capital Management LLC | 94.91M | ▼ 2.18M |
| State Street Corp | 67.32M | ▼ 2.79M |
| Primecap Management Co | 58.62M | ▲ 8.10M |
| Vanguard Portfolio Management LLC | 45.39M | ▲ 15.60M |
| Massachusetts Financial Services Co | 43.05M | ▲ 18.20M |
| Fmr LLC | 40.12M | ▼ 5.59M |
| Geode Capital Management, LLC | 34.47M | ▲ 1.03M |
| Capital World Investors | 29.32M | ▲ 12.51M |
| Arrowstreet Capital, Limited Partnership | 28.47M | ▲ 5.17M |
| Franklin Templeton Inc | 26.47M | ▲ 12.70M |
Held by 2,046 ETFs
Biggest fund positions in BSX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 4, 26 | Mahoney Michael F | other | 102,249 |
| Nov 4, 26 | Mahoney Michael F | other | 149,992 |
| Nov 1, 26 | O'Sullivan Miriam | other | 3,871 |
| Nov 1, 26 | O'Sullivan Miriam | other | 1,872 |
| Nov 1, 26 | O'Sullivan Miriam | other | 3,871 |
| Sep 2, 26 | O'Connor Padraig Andrew | other | 1,171 |
| Sep 2, 26 | O'Connor Padraig Andrew | other | 567 |
| Sep 2, 26 | O'Connor Padraig Andrew | other | 1,171 |
| Aug 25, 26 | Morano Susan E | buy | 2,040 |
| Aug 11, 26 | Woodworth Emily | other | 2,930 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BSX coverage
Recent articles, reports, and earnings notes.

Boston Scientific (BSX): Growth Reset Before the Next Upcycle
Boston Scientific is a high-quality medtech franchise with strong cash generation and a broad pipeline, but near-term growth is being pressured by EP, WATCHMAN, and China-related weakness. The stock looks attractive for patient investors, with multiple recovery catalysts still ahead.

Boston Scientific Corporation (BSX) falls on weak Q4 outlook
Boston Scientific Corporation (BSX) falls after reporting Q3 2026 results and warning that Q4 sales may decline 1% to 3% year over year. The stock’s drop reflects softer earnings, a cybersecurity-related hit, and investor concern that growth momentum is slowing despite a broad medical-device portfolio.

Encore Medical IPO: The Bull and Bear Case
Encore Medical Inc. is expected to list on the NYSE on 2026-10-01, but the price range has not been disclosed yet. The setup is straightforward: a structural heart device company with real revenue growth, but also ongoing losses and a hard regulatory path in the U.S.
Want a deeper read on BSX?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Boston Scientific announces pricing of $3.0 billion and €4.25 billion offerings of senior notes
prnewswire.com · Nov 19
BSX's Weak Solvency and Cash Conversion Raise Financing Risk
zacks.com · Nov 19
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Boston Scientific Corporation - BSX
prnewswire.com · Nov 19
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Boston Scientific Corporation - BSX
globenewswire.com · Nov 17
Boston Scientific Corporation $BSX Position Reduced by AlTi Global Inc.
defenseworld.net · Nov 17
Should You Book Profits or Hold BSX Stock Post-Q3 Earnings?
zacks.com · Nov 16
108,682 Boston Scientific Corporation $BSX Shares Bought by Aberdeen Group plc
defenseworld.net · Nov 15
Boston Scientific Targets Long-Term Growth as Key Businesses Face Pressure Through 2027
defenseworld.net · Nov 14
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 20, 2026 · Live quote · Not investment advice